Hemideina has raised funds via a private placement
Hemideina has raised US$7.4 million. The capital raised will be used to fund product development in preparation for the first human studies.
Hemideina is a Melbourne-based private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, the Hera wireless implant system. The company aims to provide a paradigm shift in hearing implant performance that will lead to increased access and adoption of treatment.
Oaklins’ team in Australia acted as lead manager in this transaction. The team has assisted Hemideina with fundraising since 2018 and is proud to support them on their mission to positively impact the lives of people with severe-to-profound hearing loss.
Elizabeth Williams
CEO and co-founder, Hemideina
Talk to the deal team
Related deals
Bayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn moreMark Climate Technology has acquired Heber GmbH
Heber GmbH has been acquired by Mark Climate Technology, a specialist in climate control systems and a portfolio company of Bolster Investment Partners. This partnership strengthens the positions of both companies in the global market for innovative and sustainable climate solutions, as well as creating unique synergies. Mark Climate's expertise in standardized, scalable solutions is enhanced by Heber's emphasis on customer-specific customization.
Learn moreGrupo Veta 2017 S.L. has been acquired by MSA Mizar
The Franco-Belgian fund Kartesia has sold Grupo Veta 2017 S.L. to the Italian group MSA Mizar. Kartesia, the main shareholder of Veta+ together with its founding partner, has sold 100% of the capital. For MSA Mizar, this transaction represents the consolidation of its presence in Spain, the entry into the multi-risk claims management market and the opportunity to apply Veta+’s expertise to other European markets.
Learn more